Name: "Anti-ALPP (MS17-57 scFv-CD79_) CBCR, NALM6"
Availability: InStock

"Anti-ALPP (MS17-57 scFv-CD79_) CBCR, NALM6" | Creative Biolabs

The integration of synthetic antigen receptors into immune cells has emerged as a powerful therapeutic strategy for treating various diseases, with T cells engineered to express chimeric antigen receptors (CAR) being a notable example for targeted cancer therapy. However, in addition to T lymphocytes, B lymphocytes have also shown promise as immune cells that can be genetically engineered for therapeutic purposes. One such approach involves using CAR-B cells to deliver monoclonal antibodies to tumor sites by targeting specific tumor-associated antigens (TAA).

Creative Biolabs has established a novel chimeric B cell receptors (CBCR) cell platform based on B leukemic cell line NALM6 to investigate the potential of CBCRs as a vehicle for adoptive immune cell therapies. B leukemic cell line NALM6 are genomically modified with the Anti-ALPP CBCR vector (Cat.# XS-0323-ZP370). The expression of CBCR is then detected to confirm the precise integration of the anti-ALPP CBCR into the appropriate locus of the B leukemic cell line NALM6.